Unless a patient who needs transcatheter aortic valve replacement (TAVR) presents with an acute coronary syndrome, "routine" percutaneous coronary intervention of coronary stenoses does not improve outcomes, even out to 5 years. Randomized clinical trials are needed to sort out the best strategies to treat the complex interaction of coronary disease and aortic stenosis, though they are unlikely to be performed. Without such evidence, patients undergoing TAVR need the judgment of a Heart Team to help strategize whether revascularization for CAD should be performed.
© 2020 Wiley Periodicals, Inc.